CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
3.670
-0.050 (-1.34%)
At close: Jul 19, 2024, 4:00 PM
3.690
+0.020 (0.54%)
Pre-market: Jul 22, 2024, 8:50 AM EDT
CureVac Employees
As of December 31, 2023, CureVac had 1,172 total employees, including 999 full-time and 173 part-time employees. The number of employees increased by 123 or 11.73% compared to the previous year.
Employees
1,172
Change (1Y)
123
Growth (1Y)
11.73%
Revenue / Employee
$54,721
Profits / Employee
-$253,470
Market Cap
823.20M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,172 | 123 | 11.73% |
Dec 31, 2022 | 1,049 | 165 | 18.67% |
Dec 31, 2021 | 884 | 330 | 59.57% |
Dec 31, 2020 | 554 | 100 | 22.03% |
Dec 31, 2019 | 454 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Healthcare Services Group | 33,400 |
The Pennant Group | 5,791 |
InnovAge Holding | 2,100 |
GeneDx Holdings | 1,000 |
Cytek Biosciences | 676 |
Clover Health Investments | 552 |
Standard BioTools | 539 |
Cogent Biosciences | 164 |
CVAC News
- 11 days ago - CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech - Accesswire
- 11 days ago - Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer - Business Wire
- 18 days ago - GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines - Barrons
- 19 days ago - CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines - Market Watch
- 19 days ago - GSK and CureVac to Restructure Collaboration into New Licensing Agreement - Accesswire
- 19 days ago - CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities - Accesswire
- 19 days ago - GSK buys full rights to make COVID, influenza vaccines from CureVac - Reuters
- 27 days ago - CureVac Announces Voting Results of General Meeting - Accesswire